Page 2 - Dan Schell News Today

In the following, we present two first-hand accounts of what it has been like to be a female working in the pharma industry for many years, and what...

We reached out to four previous Termeer Network Fellows to find out how the program helped them and what they learned. Participants included Sun...

In 2021, much of Rachel Haurwitz’ hard-earned on-the-job training over the past decade culminated in a series of significant milestones that...

Released in late 2021, Deloitte’s, “Gain An Edge With Leapfrog Digital Innovation” report talks about how the biopharma industry is...

This biotech fortified its culture during the pandemic by creating an employee support group, a new performance-management program, a woman-focused...

CEO Q&A: Dr. Aoife Brennan Source: Life Science Leader By Dan Schell, Editorial Director, Life Science Leader In our May 2019 issue, we featured Synlogic as our “Company To Watch,” and we interviewed Dr. Aoife Brennan, who has been president and CEO since May 2018. When we caught up with her in February 2021, she explained that, internally, the company is still focused on developing its “Synthetic Biotic” medicines for metabolic diseases, but it is also investigating ways to expand into...

A Q&A With A COVID-Era New CEO Source: Life Science Leader By Dan Schell, Editorial Director, Life Science Leader Becoming the CEO of a pharma company early in the COVID pandemic would be a big challenge for even a seasoned executive in this industry. Just ask David Horn Solomon, Ph.D., who took on the top role at Pharnext in April 2020. But for him, the challenge was two-fold, because the company recently had its Phase 3 trial data rejected by the FDA (for more on this part of the story, read ...